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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data upon
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College of
ardiology/American Heart Association (ACC/AHA) Task
orce on Practice Guidelines has created a new “focused
pdate” process to revise the existing guideline recommenda-
ions that are affected by the evolving data or opinion. Prior to
he initiation of this focused approach, periodic updates and
evisions of existing guidelines required up to 3 years to
omplete. Now, however, new evidence will be reviewed in an
ngoing fashion to more efficiently respond to important
cience and treatment trends that could have a major impact on
atient outcomes and quality of care. Evidence will be reviewed
t least twice a year, and updates will be initiated on an as
eeded basis as quickly as possible, while maintaining the
igorous methodology that the ACC and AHA have devel-
ped during their more than 20 years of partnership.
These updated guideline recommendations reflect a con-
ensus of expert opinion after a thorough review primarily of
ate-breaking clinical trials identified through a broad-based
etting process as important to the relevant patient popu- ration, and of other new data deemed to have an impact on
atient care (see Section 1.1 “Evidence Review” for details
egarding this focused update). It is important to note that
his focused update is not intended to represent an update
ased on a full literature review from the date of the
revious guideline publication. Specific criteria/considera-
ions for inclusion of new data include:
Publication in a peer-reviewed journal
Large randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results impacting current safety and efficacy assumptions
Strength/weakness of research methodology and findings
Likelihood of additional studies influencing current findings
Impact on current performance measure(s) and/or like-
lihood of need to develop new performance measure(s)
Requests and requirements for review and update from the
practice community, key stakeholders, and other sources
free of relationships with industry or other potential bias
Number of previous trials showing consistent results
Need for consistency with a new guideline or guideline
revision
In analyzing the data and developing updated recommen-
ations and supporting text, the focused update writing
roup used evidence-based methodologies developed by the
CC/AHA Task Force on Practice Guidelines, which are
escribed elsewhere (1).
The schema for class of recommendation and level of
vidence is summarized in Table 1, which also illustrates
ow the grading system provides an estimate of the size of
he treatment effect and an estimate of the certainty of the
reatment effect. Note that a recommendation with Level of
vidence B or C does not imply that the recommendation
s weak. Many important clinical questions addressed in
uidelines do not lend themselves to clinical trials. Although
andomized trials may not be available, there may be a very
lear clinical consensus that a particular test or therapy is
seful and effective. Both the class of recommendation and
evel of evidence listed in the focused updates are based on
onsideration of the evidence reviewed in previous iterations
f the guideline as well as the focused update. Of note, the
mplications of older studies that have informed recommen-
ations but have not been repeated in contemporary settings
re carefully considered.
The ACC/AHA practice guidelines address patient pop-
lations (and health care providers) residing in North
merica. As such, drugs that are not currently available in
orth America are discussed in the text without a specific
lass of recommendation. For studies performed in large
umbers of subjects outside of North America, each writing
ommittee reviews the potential impact of different practice
atterns and patient populations on the treatment effect and
n the relevance to the ACC/AHA target population to
etermine whether the findings should inform a specific
ecommendation.
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VHD Focused Update August 19, 2008:676–85The ACC/AHA practice guidelines are intended to assist
ealth care providers in clinical decision making by describ-
ng a range of generally acceptable approaches for the
iagnosis, management, and prevention of specific diseases
r conditions. The guidelines attempt to define practices
hat meet the needs of most patients in most circumstances.
he ultimate judgment regarding care of a particular patient
ust be made by the health care provider and patient in
ight of all the circumstances presented by that patient.
hus, there are circumstances in which deviations from
able 1. Applying Classification of Recommendations and Levehese guidelines may be appropriate. Clinical decision mak- tng should consider the quality and availability of expertise
n the area where care is provided. These guidelines may be
sed as the basis for regulatory or payer decisions, but the
ltimate goal is quality of care and serving the patient’s best
nterests.
Prescribed courses of treatment in accordance with these
ecommendations are only effective if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, health care providers should
ake every effort to engage the patient in active participa-
videncel of Eion with prescribed treatment.
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very effort to avoid any actual, potential, or perceived conflict
f interest arising from industry relationships or personal
nterests of a writing committee member. All writing commit-
ee members and peer reviewers were required to provide
isclosure statements of all such relationships pertaining to the
rials and other evidence under consideration (see Appendixes
and 2). Final recommendations were balloted to all writing
ommittee members. Writing committee members with sig-
ificant (greater than $10 000) relevant relationships with
ndustry were required to recuse themselves from voting on
hat recommendation. Writing committee members who did
ot participate are not listed as authors of this focused update.
With the exception of the recommendations presented
ere, the full guideline remains current. Only the recom-
endations from the affected section(s) of the full guideline
re included in this focused update. For easy reference, all
ecommendations from any section of a guideline impacted
y a change are presented with notation as to whether they
emain current, are new, or have been modified. When
vidence impacts recommendations in more than 1 set of
uidelines, those guidelines are updated concurrently.
The recommendations in this focused update will be con-
idered current until they are superseded by another focused
pdate or the full-text guidelines are revised. This focused
pdate is published in the August 19, 2008, issue of the Journal
f the American College of Cardiology and the August 19, 2008,
ssue of Circulation as an update to the full-text guideline, and
s also posted on the ACC (www.acc.org) and AHA (www.
mericanheart.org) Web sites. A revised version of the 2006
ull-text guideline that incorporates the focused update is
vailable on the respective Web sites (2). For easy reference,
his online-only version denotes sections that have been up-
ated.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACC/AHA Task Force on Practice Guidelines
. Introduction
.1. Evidence Review
ate-breaking clinical trials presented at the 2005 and 2006
nnual scientific meetings of the ACC, AHA, and European
ociety of Cardiology, as well as selected other data published
uring the same time period, were reviewed by the standing
uideline writing committee along with the parent task force
nd other experts to identify those trials and other key data that
ay impact guideline recommendations. On the basis of the
riteria/considerations noted above, recent trial data and other
linical data were considered when deciding whether there was
vidence important enough to prompt an update of the
CC/AHA 2006 Guidelines for the Management of Patients
ith Valvular Heart Disease (3). eThis focused update of the ACC/AHA 2006 Guidelines for
he Management of Patients With Valvular Heart Disease
potlights the 2007 AHA guidelines for infective endocarditis
rophylaxis (4). Only recommendations related to infective
ndocarditis have been revised. Individual recommendations
pdated in the present focused update will be incorporated into
uture revisions and/or updates of the full-text guidelines.
olicy on clinical areas not covered by the present focused
pdate can be found in the 2008 Focused Update Incorporated
nto the ACC/AHA 2006 Guidelines for the Management of
atients With Valvular Heart Disease (2).
.2. Organization of Committee and Relationships
ith Industry
or this focused update, all members of the 2006 Valvular
eart Disease Writing Committee were invited to partici-
ate; those who agreed (referred to as the 2008 Focused
pdate Writing Group) were required to disclose all rela-
ionships with industry relevant to the data under consid-
ration (1). Each recommendation required a confidential
ote by the writing group members before and after external
eview of the document. Any writing group member with a
ignificant (greater than $10 000) relationship with industry
elevant to the recommendation was recused from voting on
hat recommendation.
.3. Review and Approval
his document was reviewed by 2 external reviewers nomi-
ated by the ACC and 2 external reviewers nominated by the
HA, as well as 3 reviewers from the ACC Foundation’s
ACCF) Congenital Heart Disease and Pediatric Committee,
reviewers from the ACCF Cardiovascular Surgery Commit-
ee, 5 reviewers from the AHA Heart Failure and Transplant
ommittee, and 3 reviewers from the Rheumatic Fever,
ndocarditis, and Kawasaki Disease Committee. All informa-
ion about reviewers’ relationships with industry was collected
nd distributed to the writing committee and is published in
his document (see Appendix 2 for details).
This document was approved for publication by the
overning bodies of the ACCF and the AHA and endorsed
y the Society of Cardiovascular Anesthesiologists, the
ociety for Cardiovascular Angiography and Interventions,
nd the Society of Thoracic Surgeons.
.3. Endocarditis and Rheumatic Fever Prophylaxis
his focused update deals exclusively with the changes in
ecommendations for antibiotic prophylaxis against infective
ndocarditis in patients with valvular heart disease (VHD).
reatment considerations in patients with congenital heart
isease (CHD) or implanted cardiac devices are reviewed in
etail in other publications (5) and the upcoming ACC/AHA
uideline for the management of adult patients with CHD.
or an in-depth review of the rationale for the recommended
hanges in the approach to patients with VHD, the reader is
eferred to the AHA guidelines on prevention of infective
ndocarditis published online in April 2007 (4).
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d
S
pnfective endocarditis is a serious illness associated with
ignificant morbidity and mortality. Its prevention by the
ppropriate administration of antibiotics before a procedure
xpected to produce bacteremia merits serious consider-
tion. Experimental studies have suggested that endothelial
amage leads to platelet and fibrin deposition and the
ormation of nonbacterial thrombotic endocardial lesions.
able 2. Updates to Section 2.3.1. Endocarditis Prophylaxis
2006 VHD Guideline Recommendations 2008 VH
Class I
. Prophylaxis against infective endocarditis is
recommended for the following patients:
• Patients with prosthetic heart valves and patients with
a history of infective endocarditis. (Level of Evidence: C)
• Patients who have complex cyanotic congenital heart
disease (e.g., single-ventricle states, transposition of
the great arteries, tetralogy of Fallot). (Level of
Evidence: C)
• Patients with surgically constructed systemic
pulmonary shunts or conduits. (Level of Evidence: C)
• Patients with congenital cardiac valve malformations,
particularly those with bicuspid aortic valves, and
patients with acquired valvular dysfunction (e.g.,
rheumatic heart disease). (Level of Evidence: C)
• Patients who have undergone valve repair. (Level of
Evidence: C)
• Patients who have hypertrophic cardiomyopathy when
there is latent or resting obstruction. (Level of Evidence: C)
• Patients with MVP and auscultatory evidence of
valvular regurgitation and/or thickened leaflets on
echocardiography.* (Level of Evidence: C)
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C
. Prophylaxis against infective endocarditis is not
recommended for the following patients:
• Patients with isolated secundum atrial septal defect.
(Level of Evidence: C)
• Patients 6 or more months after successful surgical or
percutaneous repair of atrial septal defect, ventricular
septal defect, or patent ductus arteriosus. (Level of
Evidence: C)
• Patients with MVP without MR or thickened leaflets on
echocardiography.* (Level of Evidence: C)
• Patients with physiological, functional, or innocent
heart murmurs, including patients with aortic valve
sclerosis as defined by focal areas of increased
echogenicity and thickening of the leaflets without
restriction of motion and a peak velocity less than
2.0 m per second. (Level of Evidence: C)
• Patients with echocardiographic evidence of physiologic
MR in the absence of a murmur and with structurally
normal valves. (Level of Evidence: C)
• Patients with echocardiographic evidence of
physiological TR and/or pulmonary regurgitation in the
absence of a murmur and with structurally normal
valves. (Level of Evidence: C)
1. Prophylaxis
recommen
transesoph
esophagog
absence of
This footnote is obsolete. Please see 2006 VHD Guideline (3) for footnote text.
MR indicates mitral regurgitation; MVP, mitral valve prolapse; and TR, tricuspid regurgitation.n the presence of bacteremia, organisms may adhere to phese lesions and multiply within the platelet-fibrin com-
lex, leading to an infective vegetation. Valvular and con-
enital abnormalities, especially those associated with high-
elocity jets, can result in endothelial damage, platelet-fibrin
eposition, and a predisposition to bacterial colonization.
ince 1955, the AHA has made recommendations for
revention of infective endocarditis with antimicrobial pro-
used Update Recommendations Comments
Class IIa
nst infective endocarditis is
e following patients at highest risk
omes from infective endocarditis who
rocedures that involve manipulation
l tissue or the periapical region of
ion of the oral mucosa (4):
prosthetic cardiac valves or prosthetic
for cardiac valve repair. (Level of
previous infective endocarditis. (Level
)
CHD. (Level of Evidence: B)
cyanotic CHD, including palliative
conduits. (Level of Evidence: B)
repaired congenital heart defect
th prosthetic material or device,
ced by surgery or by catheter
, during the first 6 months after the
(Level of Evidence: B)
HD with residual defects at the site or
the site of a prosthetic patch or
evice (both of which inhibit
ization). (Level of Evidence: B)
lant recipients with valve
ue to a structurally abnormal valve.
nce: C)
Modified recommendation
(changed class of
recommendation from I to IIa,
changed text). There are no Class
I recommendations for infective
endocarditis prophylaxis.
I
st infective endocarditis is not
r nondental procedures (such as
echocardiogram,
uodenoscopy, or colonoscopy) in the
infection. (Level of Evidence: B) (4)
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August 19, 2008:676–85 VHD Focused Updateenitourinary (GU) procedures in patients at risk for its
evelopment. However, many authorities and societies, as
ell as the conclusions of published studies, have questioned
he efficacy of antimicrobial prophylaxis in most situations.
On the basis of these concerns, a writing group was
ppointed by the AHA for their expertise in prevention and
reatment of infective endocarditis, with liaison members
epresenting the American Dental Association, the Infec-
ious Disease Society of America, and the American Acad-
my of Pediatrics. The writing group reviewed the relevant
iterature regarding procedure-related bacteremia and infec-
ive endocarditis, in vitro susceptibility data of the most
ommon organisms that cause infective endocarditis, results
f prophylactic studies of animal models of infective endo-
arditis, and both retrospective and prospective studies of
revention of infective endocarditis. As a result, major
hanges were made in the recommendations for prophylaxis
gainst infective endocarditis.
The major changes in the updated recommendations
ncluded the following:
The committee concluded that only an extremely small
number of cases of infective endocarditis may be prevented
by antibiotic prophylaxis for dental procedures even if such
prophylactic therapy were 100 percent effective.
Infective endocarditis prophylaxis for dental procedures
is reasonable only for patients with underlying cardiac
conditions associated with the highest risk of adverse
outcome from infective endocarditis.
For patients with these underlying cardiac conditions,
prophylaxis is reasonable for all dental procedures that
involve manipulation of either gingival tissue or the
periapical region of teeth or perforation of oral mucosa.
Prophylaxis is not recommended solely on the basis of
an increased lifetime risk of acquisition of infective
endocarditis.
Administration of antibiotics solely to prevent endocar-
ditis is not recommended for patients who undergo a GU
or GI tract procedure.
The rationale for these revisions is based on the
ollowing:
Infective endocarditis is more likely to result from fre-
quent exposure to random bacteremias associated with
daily activities than from bacteremia caused by a dental,
GI tract, or GU procedure.
Prophylaxis may prevent an exceedingly small number of
cases of infective endocarditis (if any) in individuals who
undergo a dental, GI tract, or GU procedure.
The risk of antibiotic-associated adverse effects exceeds
the benefit (if any) from prophylactic antibiotic therapy.
Maintenance of optimal oral health and hygiene may
reduce the incidence of bacteremia from daily ac-
tivities and is more important than prophylactic antibi-
otics for a dental procedure to reduce the risk of infective
endocarditis.
2The AHA Prevention of Infective Endocarditis Commit-
ee recommended that prophylaxis be given only to a
igh-risk group of patients before dental procedures that
nvolve manipulation of either gingival tissue or the peri-
pical region of the teeth or perforation of oral mucosa
Tables 2 to 4). High-risk patients were defined as those
atients with underlying cardiac conditions associated with
he highest risk of adverse outcome from infective endocar-
itis, not necessarily those with an increased lifetime risk of
cquisition of infective endocarditis. Prophylaxis is no
onger recommended for prevention of endocarditis for
rocedures that involve the respiratory tract unless the
rocedure is performed in a high-risk patient and involves
ncision of the respiratory tract mucosa, such as tonsillec-
omy and adenoidectomy. Prophylaxis is no longer recom-
ended for prevention of infective endocarditis for GI or
U procedures, including diagnostic esophagogastroduode-
oscopy or colonoscopy (Table 2). However, in high-risk
atients with infections of the GI or GU tract, it is
easonable to administer antibiotic therapy to prevent
ound infection or sepsis. For high-risk patients undergo-
ng elective cystoscopy or other urinary tract manipulation
ho have enterococcal urinary tract infection or coloniza-
ion, antibiotic therapy to eradicate enterococci from the
rine before the procedure is reasonable.
These changes are a significant departure from the past
HA (7) and European Society of Cardiology (8) recom-
endations for prevention of infective endocarditis and may
iolate longstanding expectations in practice patterns of
atients and health care providers. However, the writing
ommittee for these updated guidelines consists of experts
n the field of infective endocarditis; input was also obtained
rom experts not affiliated with the writing group. All data
o date were reviewed thoroughly, and the current recom-
endations reflect analysis of all relevant literature. This
ultidisciplinary team of experts emphasizes that previously
ublished guidelines for the prevention of endocarditis
ontained ambiguities and inconsistencies and relied more
n opinion than on data. The writing committee delineates
able 3. Endocarditis Prophylaxis for Dental Procedures*
Reasonable Not Recommended
ndocarditis prophylaxis is
reasonable for patients
with the highest risk of
adverse outcomes who
undergo dental
procedures that involve
manipulation of either
gingival tissue or the
periapical region of
teeth or perforation of
the oral mucosa.
Endocarditis prophylaxis is not
recommended for:
• Routine anesthetic injections through
noninfected tissue
• Dental radiographs
• Placement or removal of
prosthodontic or orthodontic
appliances
• Adjustment of orthodontic appliances
• Placement of orthodontic brackets
• Shedding of deciduous teeth
• Bleeding from trauma to the lips or
oral mucosa
This table corresponds to Table 6 in the 2008 Focused Update Incorporated Into the ACC/AHA
006 Guidelines for the Management of Valvular Heart Disease (2).
Adapted with permission (6).
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VHD Focused Update August 19, 2008:676–85he reasons with which evolutionary refinement in the
pproach to infective endocarditis prophylaxis can be justi-
ed. In determining which patients receive prophylaxis,
here is a clear focus on the risk of adverse outcomes after
nfective endocarditis rather than the lifetime risk of acqui-
ition of infective endocarditis. The current recommenda-
ions result in greater clarity for patients, health care
roviders, and consulting professionals.
Other international societies have published recommen-
ations and guidelines for the prevention of infective endo-
arditis. New recommendations from the British Society for
ntimicrobial Chemotherapy are similar to the current
HA recommendations for prophylaxis before dental pro-
edures. The British Society for Antimicrobial Chemother-
py did differ in continuing to recommend prophylaxis for
igh-risk patients before GI or GU procedures associated
ith bacteremia or endocarditis (9).
Therefore, Class IIa indications for prophylaxis against
nfective endocarditis are reasonable for VHD patients at
ighest risk for adverse outcomes from infective endocardi-
is before dental procedures that involve manipulation of
ither gingival tissue. This high-risk group includes: 1)
atients with a prosthetic heart valve or prosthetic material
sed for valve repair, 2) patients with a past history of
nfective endocarditis, and 3) patients with cardiac valvu-
opathy after cardiac transplantation, as well as 4) specific
atients with CHD (Table 2). Patients with innocent
urmurs and those patients who have abnormal echocar-
iographic findings without an audible murmur should
efinitely not be given prophylaxis for infective endocarditis.
nfective endocarditis prophylaxis is not necessary for non-
ental procedures that do not penetrate the mucosa, such as
ransesophageal echocardiography, diagnostic bronchos-
opy, esophagogastroscopy, or colonoscopy, in the absence
able 4. Regimens for a Dental Procedure*
Situation
ral A
nable to take oral medication A
O
C
llergic to penicillins or ampicillin—oral C
O
C
O
A
llergic to penicillins or ampicillin and unable to take oral medication C
O
C
This table corresponds to Table 7 in the 2008 Focused Update Incorporated Into the ACC
econd-generation oral cephalosporin in equivalent adult or pediatric dosage. ‡Cephalosporins s
r ampicillin.
IM indicates intramuscular; and IV, intravenous.f active infection. aThe committee recognizes that decades of previous
ecommendations for patients with most forms of VHD
nd other conditions have been abruptly changed by the
ew AHA guidelines (4). Because this may cause con-
ternation among patients, clinicians should be available
o discuss the rationale for these new changes with their
atients, including the lack of scientific evidence to
emonstrate a proven benefit for infective endocarditis
rophylaxis. In select circumstances, the committee also
nderstands that some clinicians and some patients may
till feel more comfortable continuing with prophylaxis
or infective endocarditis, particularly for those with
icuspid aortic valve or coarctation of the aorta, severe
itral valve prolapse, or hypertrophic obstructive cardio-
yopathy. In those settings, the clinician should deter-
ine that the risks associated with antibiotics are low
efore continuing a prophylaxis regimen. Over time, and
ith continuing education, the committee anticipates
ncreasing acceptance of the new guidelines among both
rovider and patient communities.
A multicenter randomized, controlled trial has never been
erformed to evaluate the efficacy of infective endocarditis
rophylaxis in patients who undergo dental, GI, or GU
rocedures. On the basis of these new recommendations,
ewer patients will receive infective endocarditis prophylaxis.
t is hoped that the revised recommendations will stimulate
roperly designed prospective studies on the prevention of
nfective endocarditis.
Tables 5 and 8 of the 2006 Valvular Heart Disease
uideline (3) are now obsolete. Please disregard these tables.
.1.4.4. AORTIC STENOSIS: MEDICAL THERAPY
ntibiotic prophylaxis is no longer indicated in patients with
Regimen: Single Dose 30 to 60 min
Before Procedure
Agent Adults Children
cillin 2 g 50 mg/kg
illin 2 g IM or IV 50 mg/kg IM or IV
lin or ceftriaxone 1 g IM or IV 50 mg/kg IM or IV
lexin†‡ 2 g 50 mg/kg
mycin 600 mg 20 mg/kg
mycin or clarithromycin 500 mg 15 mg/kg
lin or ceftriaxone‡ 1 g IM or IV 50 mg/kg IM or IV
mycin 600 mg IM or IV 20 mg/kg IM or IV
006 Guidelines for the Management of Valvular Heart Disease (2). †Or use other first- or
ot be used in an individual with a history of anaphylaxis, angioedema, or urticaria with penicillinsmoxi
mpic
R
efazo
epha
R
linda
R
zithro
efazo
R
linda
/AHA 2
hould nortic stenosis for prevention of infective endocarditis.
3A
m
3
a
A
m
3
P
A
m
6
D
A
a
o
6
P
A
a
o
S
A
J
C
L
M
B
K
E
A
M
G
P
A
H
D
D
D
D
D
D
D
D
T
c
i
e
u
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ntibiotic prophylaxis is no longer indicated in patients with
itral stenosis for prevention of infective endocarditis.
.5.2. Evaluation and Management of the Asymptom-
tic Patient With Mitral Valve Prolapse
ntibiotic prophylaxis is no longer indicated in all patients with
itral valve prolapse for prevention of infective endocarditis.
.5.3. Evaluation and Management of the Symptomatic
atient With Mitral Valve Prolapse
ntibiotic prophylaxis is no longer indicated in all patients with
itral valve prolapse for prevention of infective endocarditis.
. Management of Congenital Valvular Heart
isease in Adolescents and Young Adults
ntibiotic prophylaxis is no longer indicated in the adolescent
nd young adult with native heart valve disease for prevention
f infective endocarditis. K.6.3. Indications for Balloon Valvotomy in
ulmonic Stenosis
ntibiotic prophylaxis is no longer indicated in the adolescent
nd young adult with native heart valve disease for prevention
f infective endocarditis.
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